Prevalence of phosphodiesterase-5 inhibitor use in the VHA in 2004 and 2005 is twice that of a commercial health plan in 2001

Dustin D. French*, Curtis E. Margo, Robert R. Campbell

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)692-693
Number of pages2
JournalJournal of Managed Care Pharmacy
Volume12
Issue number8
DOIs
StatePublished - Oct 2006

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy

Cite this